Do Health Screenings Benefit Older Adults?

In this post I discuss the use, value, and the downside of health screening tests. Used wisely, they can potentially improve wellness and increase life span. But the benefit may not be as much as you might think, especially as you get older. Learn more in this post.

This information is current as of the date of original publication or update but may have changed by the time you read this. Do not use this information for diagnosis or treatment purposes. Before making health decisions, discuss with a qualified healthcare professional.

One way physicians help people stay healthy is by offering screening tests. These tests can detect conditions for which prevention or treatment increase life span, prevents disability, and promotes wellness.

Screening tests are for people without symptoms of the condition in question. Recommendations for screening are usually based on patient-specific factors such as gender, age, family history, health habits, and other medical issues.

Screening tests recommended by medical organizations or governmental health agencies are usually covered by insurance without a copay.

Screening tests can be inconvenient and uncomfortable. They may create anxiety if further testing is needed to confirm results. These expenses may not be covered by insurance.

Most of the time, screening tests find no disease.

As we get older and remain healthy, it is reasonable to question whether screening tests are necessary or even helpful. Might it actually be harmful to screen older adults for conditions they likely never will develop, or if they do, will not cause premature death?

Doctors and patients are asking that question more often. This article from KFF Health News explores those questions.

3 Medical Routines That Older People May Not Need

By Paula Span, May 22, 2026

Enough time had passed since the patient’s previous colonoscopy that she met the criteria to undergo another, said Steven Itzkowitz, a gastroenterologist at the Icahn School of Medicine at Mount Sinai in New York.

She was in “reasonably good health,” and the risks of the procedure — bleeding, reaction to anesthesia, perforation of her colon — were fairly low. But she was 85. And she would need to briefly discontinue the blood thinners she took because of the cardiac stents keeping her arteries open; doing so could increase the risks.

Had Itzkowitz and his patient faced this decision five years ago, he might have scheduled the screening “without even thinking about it,” he said. But recent research has shown again that the benefits of a repeat colonoscopy are slim after age 75.

Now, he said, “I’m saying to myself, ‘What are we accomplishing here?’”

He’s not the only doctor — or patient — having second thoughts. The risks and benefits of common screenings, procedures, and drugs add up differently at advanced ages, and research continues to point out fresh examples of some that may become unnecessary.

Recently, investigators have taken on questions about common skin lesions that probably don’t need to be removed, a widely used thyroid medication that many older patients can safely discontinue, and colonoscopies that reduce colon cancer mortality so slightly that the risks may outweigh the benefits.

Ugly but Probably Harmless-Actinic Keratosis

The reddened or rough patches on the skin are called, in doctor-speak, actinic keratoses. Because they result from long-term sun exposure, they usually appear on faces, scalps, forearms, and the backs of hands.

Such lesions appear most commonly on older patients. One large study of traditional Medicare beneficiaries found that over a five-year period, almost 30% were diagnosed with an actinic keratosis. Then what?

Layers of the Skin diagram
The layers of the skin (epidermis and dermis), as well as an inset with a close-up view of the types of cells in the skin (squamous cells, basal cells, and melanocytes).
Source: National Cancer Institute
Creator: Don Bliss (Illustrator)
This image is in the public domain and can be freely reused. Please credit the source and, where possible, the creator listed above.

“The vast majority of the time, they’re removed,” said Allison Billi, a dermatologist at the University of Michigan and an author of a recent commentary on the topic in JAMA Internal Medicine. That typically involves cryosurgery (freezing with liquid nitrogen), topical creams, or laser therapy.

The rationale: The patches could become cancerous. But “for the average patient with no history of skin cancer, there is less than a 1-in-1,000 chance of it progressing to skin cancer,” Billi said, citing a 2013 meta-analysis. The lesions are far more likely to disappear on their own.

“The treatment may be more burdensome than the condition itself,” she added. Removal “is actually extremely painful, both during and after.” It can cause swelling, irritation, and lasting discoloration.

Besides, an actinic keratosis will probably reappear, or new ones will emerge. “This is a chronic condition,” Billi said.

She has proposed active surveillance, instead: Primary care doctors could observe the lesions annually for warning signs like bleeding, pain, or rapid growth, which might warrant removal. But “in many cases, it’s not necessary,” she said.

She does recommend using sunscreen, however. (affiliate)

“We don’t always need to do everything we can do.”

Dr. Allison Billi, dermatologist

Questionable Treatment-Hypothyroidism

Patients take levothyroxine, one of the world’s most frequently prescribed drugs, when their thyroid glands can’t produce sufficient thyroid hormone.

With this condition, called hypothyroidism, “people gain weight. They have less energy. Their hair and skin are dry,” explained Jacobijn Gussekloo, a primary care doctor and researcher at Leiden University Medical Center in the Netherlands. “Everything slows down.”

Doctors also increasingly prescribe it for a borderline condition called subclinical hypothyroidism, which usually causes no symptoms but can progress to hypothyroidism.

The thyroid gland, showing a tumor, original source NCI

Most patients take the drug for life — but do they have to? Gussekloo’s team has found that in many older adults with subclinical hypothyroidism, hormone levels normalize on their own.

The researchers have also reported that among older people with the condition, levothyroxine had no effect on symptoms and “no apparent benefit.”

Like any drug, it can also cause harm. It may interact with other medications that older patients typically take. Moreover, “it requires frequent lab tests and follow-ups, more visits and expense,” said Maria Papaleontiou, an endocrinologist at the University of Michigan and an author of an editorial in JAMA accompanying the latest Dutch study.

“In high doses, it can cause hyperthyroidism, which can lead to cardiac arrhythmias and bone loss,” she added. Patients taking it also have to adjust their diets and meal schedules.

To determine whether some patients could stop taking levothyroxine, the Dutch researchers devised a protocol that gradually reduced doses over 30 weeks, with ongoing lab testing and consultations with doctors.

After a year, a quarter of the 370 participants, all over 60, had discontinued the drug while maintaining healthy thyroid function. Most had been on lower doses to begin with.

Patients shouldn’t stop levothyroxine on their own, Papaleontiou cautioned. Discontinuation requires tapering off gradually, with testing and monitoring. Some patients will always need the drug.

But it appears that “a select group of adults over 60 may not require this treatment lifelong,” Papaleontiou said.

A Screening With Risks-Colonoscopy

The question of when older patients can safely stop screening for colon cancer has prompted years of debate. The influential U.S. Preventive Services Task Force gives the screening a lukewarm C rating after age 76, calling the benefit “small.”

Yet almost 60% of older patients who have had previous colonoscopies and face limited life expectancies (less than five years) are advised to undergo another screening, a 2023 study found.

diagram of the human digestive organs
The colon sits between the small intestine and the rectum, the green structure on this diagram. Stock image, source unknown

As a gastroenterologist at the University of California-San Diego, Samir Gupta regularly encounters this issue with older patients. “I know they really have a low risk of colon cancer, and I’m putting them through more risk,” he said.

The risk of complications following a colonoscopy rise with age. One study found that nearly 7% of patients over 75 had a hospitalization or emergency room visit within a month of the procedure.

Is it worth it? Gupta is the lead author of a new study of almost 92,000 Veterans Affairs patients over 75 who had previous colonoscopies. In about 28%, the procedure had found an adenoma, a type of polyp that can become cancerous. Though only a small fraction do, gastroenterologists generally remove them.

The researchers found that after 10 years, veterans with a previous adenoma were more likely to develop colon cancer than those without one, though the rate was extremely low in both groups.

But just 0.5% — yes, one-half of 1% — of those with a previous adenoma died of colon cancer, compared with 0.4% of those without one. “A tiny difference,” Gupta said.

Both groups were dwarfed by the number of veterans — almost half — who died within the decade of other causes.

“Even if the procedure goes well, you’ll either find nothing or you’ll find something that’s not going to have real impact on your longevity,” said Itzkowitz, an author of an editorial published alongside the study.

Yet he has found that many patients who have had polyps removed want to continue colonoscopies.

It is hard to shift established medical norms. Efforts to “deprescribe” drugs can meet with opposition from both patients and health care professionals.

Many older women continue having mammograms past the point of documented benefit, and older men often undergo prostate cancer screening beyond the recommended age.

chance of developing breast cancer by age 70-National Cancer Institute
Source: National Cancer Institute (NCI)

Colonoscopies are less pleasant, so perhaps older patients will be glad to forgo them. “Even with polyps, the chance of dying from colon cancer is so low compared to everything else that can get you,” Itzkowitz said.

So he told his 85-year-old patient that she could skip another colonoscopy. She seemed pleased.

The New Old Age is produced through a partnership with The New York Times.

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.

This article first appeared on KFF Health News and is republished here under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Images in this Post

The graphics were not in the original KFF article. The cover image was generated by AI in WordPress.

Exploring your health

Screening medical tests are not just for older people. Screening evaluations are recommended for people of all ages. all ages.

Do you know what screening tests are recommended for you? You can consult an online resource, but the best source is your own personal physician, who knows your past, current, and family medical history.

What does or would motivate you to have screening tests, or not?

What benefit, or not, have you received from screening tests?

Exploring the HEART of Health

I appreciate your time reading this post and invite you to follow this blog and me on social media.

I share information and inspiration to help you transform challenges into opportunities for learning and growth.

Add your name to the subscribe box to be notified of new posts by email. Click the link to read the post and browse other content. It’s that simple. No spam.

I enjoy seeing who is new to Watercress Words. When you subscribe, I will visit your blog or website. Thanks and see you next time.

Dr. Aletha

Transforming Mental Illness Diagnosis and Treatment with Biomarkers

In this article I discuss potential use of biomarkers to diagnose and treat psychiatric disorders, particularly depression. Research is underway to identify these which could improve diagnosis and treatment, though concerns about cost, insurance, and privacy persist. Adequate funding for research is crucial.

This information is current as of the date of original publication or update but may have changed by the time you read this. Do not use this information for diagnosis or treatment purposes. Before making health decisions, discuss with a qualified healthcare professional.

Imagine you consult a physician for a problem. The doctor asks you questions and examines you. Then you have blood tests, cultures, X-rays,a CT scan or MRI. You hope these tests show what is “wrong” so the doctor can treat you.

But what if all the tests are “normal”? Normal tests suggest that your symptoms may be due to a cause for which there is no biomarker.

A biomarker is a diagnostic test that indicates a specific disease or condition.

biomarker-A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.

Both physicians and patients would like a biomarker for every disease. But many common conditions do not yet have a biomarker.

These include migraine, fibromyalgia, irritable bowel syndrome, Parkinson’s disease, many skin conditions, Alzheimer’s dementia, depression, and other psychiatric disorders.

a female physician talking to a male patient

For these disorders, physicians make a “clinical diagnosis”.

clinical diagnosis-The process of identifying a disease, condition, or injury based on the signs and symptoms a patient is having and the patient’s health history and physical exam

Much of medical research is devoted to finding biomarkers for these and other conditions. This article from KFF focuses on finding biomarkers for psychiatric disorders, especially depression. Such tests could be helpful not only for diagnosis but also for guiding therapy.

But there are potential downsides, like cost, insurance coverage, privacy, and potential discrimination, as explained in the article.

Psychiatrists’ Use of Biomarkers Could Open a New Window Into Mental Health Diagnoses

by Jamie Ducharme, March 17, 2026

Amanda Miller was 30 and pregnant with her second child in Hershey, Pennsylvania, when she developed depression. After she gave birth, her depression worsened. It was joined by a slew of unexplained health problems.

Miller, a neuroscientist, said she saw several psychiatrists and got prescriptions for drug after drug. Over two years, she tried four antidepressants and two antipsychotics. None of that helped — until her primary care doctor noticed high levels of an autoimmune marker in her blood.

A specialist then ran “every test in the book,” Miller said. Eventually, she was diagnosed with the autoimmune disease lupus and prescribed an inflammation-lowering steroid. Some of her symptoms let up within hours. Her depression subsided not long after.

“I was convinced it was a placebo effect,” Miller said, “but then it kept working.”

Had inflammation been contributing to her mental health problems all along? Miller thinks so, although she can’t know for sure. Her psychiatrists never raised that possibility, she said.

Laboratory vs Clinical Diagnosing

In most medical specialties, doctors can confirm whether to pursue a type of treatment through tests, such as blood work, imaging, and biopsies. Mental illnesses, however, have historically been diagnosed and treated based on outward symptoms. That could change.

The American Psychiatric Association in a January paper included ideas for how it might incorporate biomarkers — biological indicators of mental illness that could show up on diagnostic tests — into future versions of its Diagnostic and Statistical Manual of Mental Disorders.

The DSM, sometimes called “psychiatry’s bible” because of its influence in the field, provides criteria for diagnoses. It’s used by clinicians assessing patients and by insurance companies deciding whether to cover care.

‘Coordinated’ Research Needed

Psychiatric biomarkers are not ready for widespread use yet, the paper emphasized. Scientists have researched the topic for decades, with little to show for it.

More research is needed to prove these metrics are valid and reliable enough to be used in patient care, the APA’s paper said, and other researchers have raised questions about how their use could affect health care costs, insurance coverage, and patient privacy.

Adding biomarkers to the DSM would be “a very big deal,” said Jonathan Alpert, an author of the January paper and vice chair of the APA’s Future DSM Strategic Committee.

Access to test results, along with symptoms, could streamline insurance coverage decisions and help clinicians make faster and more accurate diagnoses and treatment recommendations, he said. If patients’ biology suggested they’d respond better to one treatment than another, their doctor could waste no time in starting there.

A Prescribing “Crapshoot”

Currently, prescribing psychiatric medications can be “a bit of a crapshoot,” with clinicians unable to predict whether they will work for a particular patient, said Matthew Eisenberg, director of the Center for Mental Health and Addiction Policy at the Johns Hopkins University Bloomberg School of Public Health.

In a seminal, early 2000s trial funded by the National Institute of Mental Health, about 30% of the study’s participants with depression saw symptoms disappear with their first antidepressant treatment. That study is still one of the most robust antidepressant trials conducted — although researchers have more recently argued that fewer people are cured by these medications than its results suggest.

9 different medication pills and capsules of various colors

Such a trial-and-error approach can lead to ineffective and unnecessary prescriptions, a topic of attack by proponents of the Make America Healthy Again movement, spearheaded by Health and Human Services Secretary Robert F. Kennedy Jr. Kennedy has been especially critical of antidepressants, having linked them to violence after a mass shooting without evidence and blaming doctors for overprescribing medications for children.

HHS is analyzing psychiatric diagnosis and prescription trends and evaluating alternative mental health treatment approaches, with a particular focus on children, spokesperson Emily Hilliard said in a statement. Hilliard did not respond to a question about Kennedy’s previous comments.

Biomarkers are already used to guide treatment in other medical disciplines, such as oncology. Arizona, Georgia, Kentucky, Texas, and more than a dozen other states require insurers to cover such testing. Blood and imaging tests are now used to help diagnose Alzheimer’s disease as well.

A Future for Psychiatric Biomarkers

The APA included in its article a variety of ways psychiatric biomarkers could be used in the future — such as testing for brain activity, genetic profiles, or immune markers associated with certain psychiatric conditions, including schizophrenia and substance use disorders.

In depression, for example, about a quarter of patients have elevated levels of an inflammatory protein, called C-reactive protein, that can be found through a blood test.

Research has shown that people with high levels of this protein seem to respond better when given drugs that alter dopamine levels in the brain, rather than using only selective serotonin reuptake inhibitors, or SSRIs, a common type of antidepressant.

C-reactive protein still needs to be “robustly validated” as a biomarker, but it’s among the most promising currently under investigation.

APA

A “coordinated, well-funded” research effort is needed to achieve such validation, the APA wrote — a tenuous prospect since the Trump administration slashed funding for research.

The National Institute of Mental Health alone had at least 128 grants, worth almost $173 million, canceled in 2025, according to a research letter in the journal JAMA. Though some grants have since been restored, researchers relying on federal money still fear their work is vulnerable to cuts.

“There’s a great need for continued, active funding of research related to mental health,” Alpert said, but scientists will have to grapple with “uncertainties of the funding landscape.”

Ripple Effects on Coverage, Costs

Health care costs tend to be higher among patients with poorly controlled mental illnesses, due to expenses like hospital visits, outpatient appointments, and prescriptions. Some research suggests biomarker testing could save money by landing on the right treatments faster and avoiding some of these costs.

One modeling study estimated that testing to look for genetic components that may influence a drug’s effectiveness could save the Canadian health system $956 million over 20 years if used among adults with major depression in British Columbia. Another study, by Spanish researchers, found that such testing reduced costs for most of the 188 participants with serious mental illness.

Whether the same would be true in the U.S. health care system is unknown. In the short term, Johns Hopkins’ Eisenberg said, an approach that uses biomarkers could raise health care spending due to the costs of testing.

Insurers may decline to cover pricey biomarker tests, It takes a while for new science to be proven safe and effective,
And once it is, insurance companies don’t cover it immediately.”

Matthew Eisenberg, Johns Hopkins

“The Beginning of a Revolution”

Some researchers have raised concerns that insurers or employers could discriminate against people whose biological profiles suggest they’re at risk of developing serious neuropsychiatric conditions.

It’s a “critical moment” to consider legislative approaches to protect patients and train clinicians about how to appropriately use these tools, said Gabriel Lázaro-Muñoz, a member of Harvard Medical School’s Center for Bioethics.

“I do not think that the field of psychiatry is currently ready to manage this,” he said.

The mental health system isn’t ready to “jump in with both feet,” said Andrew Miller, a professor of psychiatry and behavioral sciences at the Emory University School of Medicine, who studies inflammation-related depression. But the APA’s embrace of biomarkers signals “the beginning of a revolution,” he said.

“This is a recognition … that what we’ve done up to this point has not been good enough,” Miller said. “And we can do better.”

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.

USE OUR CONTENT

This story can be republished for free (details).KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.

Subscribe to KFF Health News’ free Morning Briefing.

This article first appeared on KFF Health News and is republished here under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Depression

Depression is common among people who have a chronic disease such as cancer or diabetes. Fortunately, depression is treatable even if you have another medical illness or condition. Learn more about chronic disease and depression: Caring for your mental health #shareNIMH

Biomarkers in Cancer Care

Biomarker testing is a way to look for genes, proteins, and other substances (called biomarkers or tumor markers) that can provide information about cancer. Each person’s cancer has a unique pattern of biomarkers.

Some biomarkers affect how certain cancer treatments work. Biomarker testing may help you and your doctor choose a cancer treatment for you.

There are also other kinds of biomarkers that can help doctors diagnose and monitor cancer during and after treatment. To learn more, visit the Tumor Markers fact sheet.

Biomarker testing is for people who have cancer. People with solid tumors and people with blood cancer can get biomarker testing.

The FDA-approved blood tests for diagnosing Alzheimer’s disease

In May 2025, the U.S. Food and Drug Administration (FDA) approved the first blood test as a tool to help diagnose Alzheimer’s disease. The test is called Lumipulse.

The test measures certain proteins, including a specific form of the tau protein. This can indicate amyloid plaques in the brain, a protein that is considered the hallmark sign of Alzheimer’s disease.

This blood test, along with other diagnostic tools can help diagnose Alzheimer’s disease. While the blood test can detect changes even before memory problems begin, it is only recommended for use in people showing symptoms of Alzheimer’s disease.

The test is still being refined and can’t diagnose Alzheimer’s disease on its own. 

What to Remember from this Post

I learned from the KFF article and the references, did you? What are your takeaways from what you read? Here are some to consider.

  • Doctors use laboratory tests and imaging to supplement information gleaned from talking to and examining patients.
  • Biomarkers for common conditions make diagnosis easier and more precise, and help guide therapy.
  • Discovery of biomarkers for other serious conditions will help patients get earlier diagnosis and more effective treatment. More research is needed.
  • New medical discoveries introduce trade-offs in cost, payment, benefit, and potential misuse.

How will you use what you’ve learned? How may you apply this information to a current or future health concern?

What more information do you need and where will you find it?

a stethoscope, a red heart and a heart ekg tracing
exploring the HEART of HEALTH

Exploring the HEART of Health

I appreciate your time reading this post and invite you to follow this blog and me on social media.

I share information and inspiration to help you transform challenges into opportunities for learning and growth.

Add your name to the subscribe box to be notified of new posts by email. Click the link to read the post and browse other content. It’s that simple. No spam.

I enjoy seeing who is new to Watercress Words. When you subscribe, I will visit your blog or website. Thanks and see you next time.

Use this search box for related posts on this blog or other topics of interest to you.

Dr. Aletha